Home › Funds › Catalio Capital Management, LP › RARE

Catalio Capital Management, LP position in RARE

ULTRAGENYX PHARMACEUTICAL IN · Health Care

Catalio Capital Management, LP reported holding 316,252 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$10.6M, representing 1.98% of its reported portfolio and ranking #20 among its reported holdings. Catalio Capital Management, LP has disclosed RARE holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)316.25K sh
Reported value held$10.56M
Portfolio Weight1.98%
First reportedQ2 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Catalio Capital Management, LP's RARE position evolved

Catalio Capital Management, LP first disclosed a stake in RARE in Q2 2025 at 213,402 shares (US$7.8M). The position peaked in Q1 2026 at 850,797 shares, worth US$17.8M. Across 5 filings, Catalio Capital Management, LP increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 316,252 shares valued at US$10.6M — a reduction of -534,545 shares quarter over quarter.. Notable position changes include a 44% trim in Q4 2025 (shares fell 9% over the following quarter), a 423% increase in Q1 2026 (shares rose 59% over the following quarter), a 63% trim in Q2 2026 (shares fell 55% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 213.40K $7.76M New
Q3 2025 291.26K $8.76M Add
Q4 2025 162.55K $3.74M Reduce
Q1 2026 850.80K $17.82M Add
Q2 2026 316.25K $10.56M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RARE and 13F data

RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 27 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RARE

All RARE fund holders →

FAQ

How long has Catalio Capital Management, LP held RARE?

Catalio Capital Management, LP has disclosed RARE holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Catalio Capital Management, LP's current position in RARE?

As of Q2 2026, Catalio Capital Management, LP holds 316.25K shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $10.56M, representing 1.98% of its reported portfolio and ranking #20.

Has Catalio Capital Management, LP been buying or selling RARE?

In the latest 13F filing (Q2 2026), Catalio Capital Management, LP reduced its position in RARE. The position peaked in Q1 2026 at 850.80K shares.

Which other funds hold RARE?

Other major institutional holders of RARE include RTW INVESTMENTS, LP, SANDS CAPITAL MANAGEMENT, LLC, FRONTIER CAPITAL MANAGEMENT CO LLC, among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.